Eg5 Antibody (10C7/Eg5): sc-53691

Eg5 Antibody (10C7/Eg5) is a mouse monoclonal IgG1 antibody that detects KIF11 in mouse, rat, and human samples through western blotting (WB) and immunoprecipitation (IP) applications. Anti-KIF11 antibody (10C7/Eg5) plays a crucial role in studying KIF11, a vital microtubule-based motor protein essential for bipolar spindle formation during eukaryotic cell division. KIF11, also known as kinesin family member 11 or Eg5, is a member of the BimC kinesin family and is characterized by slow, plus-end-directed motility along microtubules. Proper functioning of KIF11 is critical, as KIF11 facilitates centrosome movement, ensuring accurate chromosome segregation during mitosis. Disruption of KIF11 expression leads to halting of centrosome migration and results in cells being arrested in mitosis with monoastral microtubule arrays, which can have significant implications for cell proliferation and cancer research. Additionally, KIF11 undergoes post-translational modifications, including phosphorylation on serine during S phase and on both serine and threonine 927 during mitosis, which are essential for regulating KIF11′s interaction with the spindle apparatus, particularly during early prophase. Understanding these modifications and their effects on KIF11′s function can provide insights into mechanisms of cell division and potential development of therapeutic strategies targeting mitotic processes in various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Eg5 Antibody (10C7/Eg5) References:

1. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.  |  Hu, ZD., et al. 2021. Biomed Res Int. 2021: 2676745. PMID: 33490265
2. Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance.  |  Liu, B., et al. 2022. Cell Mol Neurobiol. 42: 1477-1485. PMID: 33491154
3. KIF11 as a potential cancer prognostic marker promotes tumorigenesis in children with Wilms tumor.  |  Luo, Y., et al. 2022. Pediatr Hematol Oncol. 39: 145-157. PMID: 34378481
4. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.  |  Gu, X., et al. 2022. Cancer Med. 11: 3282-3295. PMID: 35619540
5. Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.  |  Sun, RF., et al. 2023. Curr Cancer Drug Targets. 23: 293-306. PMID: 35713129
6. LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A.  |  Chen, D., et al. 2023. Clin Transl Med. 13: e1418. PMID: 37752791
7. Inhibition of KIF11 ameliorates osteoclastogenesis via regulating mTORC1-mediated NF-κB signaling.  |  Miao, J., et al. 2023. Biochem Pharmacol. 217: 115817. PMID: 37757917
8. Loss-of-function of kinesin-5 KIF11 causes microcephaly, chorioretinopathy, and developmental disorders through chromosome instability and cell cycle arrest.  |  Zhou, Y., et al. 2024. Exp Cell Res. 436: 113975. PMID: 38367657
9. KIF11 UFMylation Maintains Photoreceptor Cilium Integrity and Retinal Homeostasis.  |  Ran, J., et al. 2024. Adv Sci (Weinh). 11: e2400569. PMID: 38666385
10. Mitotic Functions and Characters of KIF11 in Cancers.  |  Gao, W., et al. 2024. Biomolecules. 14: PMID: 38672404

The preferred Eg5 antibody is Eg5 Antibody (F-1): sc-374212.